TABLE 2.
Univariate logistic regression for the presence of different metastatic sites at diagnosis of colorectal cancer
| Liver metastasis | Lung metastasis | Bone metastasis | Brain metastasis | |||||
|---|---|---|---|---|---|---|---|---|
| Characteristics | HR (95% CI) | P‐value | HR (95% CI) | P‐value | HR (95% CI) | P‐value | HR (95% CI) | P‐value |
| Age at diagnosis | <.001 | <.001 | <.001 | .014 | ||||
| <60 | 1 | 1 | 1 | 1 | ||||
| ≥60 | 0.629 (0.605‐0.654) | <.001 | 0.724 (0.670‐0.782) | <.001 | 0.684 (0.562‐0.833) | <.001 | 0.639 (0.447‐0.914) | .014 |
| Race | <.001 | <.001 | .076 | .538 | ||||
| White | 1 | 1 | 1 | 1 | ||||
| Black | 1.450 (1.374‐1.531) | <.001 | 1.283 (1.136‐1.449) | <.001 | 0.926 (0.653‐1.314) | .668 | 0.676 (0.329‐1.389) | .832 |
| Other | 0.987 (0.923‐1.055) | .701 | 1.540 (1.387‐1.710) | <.001 | 1.352 (1.028‐1.780) | .031 | 1.061 (0.616‐1.826) | .286 |
| Gender | <.001 | .208 | .038 | .947 | ||||
| Female | 1 | 1 | 1 | 1 | ||||
| Male | 1.182 (1.137‐1.228) | <.001 | 1.050 (0.973‐1.132) | .208 | 1.229 (1.011‐1.494) | .038 | 0.988 (0.693‐1.409) | .947 |
| Site | <.001 | <.001 | .307 | .216 | ||||
| Rectum | 1 | 1 | 1 | 1 | ||||
| Left colon | 2.043 (1.914‐2.181) | <.001 | 1.320 (1.179‐1.478) | <.001 | 1.192 (0.893‐1.592) | .234 | 1.516 (0.826‐2.781) | .179 |
| Right colon | 1.718 (1.612‐1.831) | <.001 | 1.007 (0.901‐1.125) | .900 | 1.027 (0.776‐1.358) | .853 | 1.672 (0.940‐2.975) | .080 |
| CEA | <.001 | <.001 | <.001 | <.001 | ||||
| Positive | 1 | 1 | 1 | 1 | ||||
| Negative | 0.257 (0.246‐0.268) | <.001 | 0.319 (0.293‐0.347) | <.001 | 0.284 (0.228‐0.354) | <.001 | 0.267 (0.175‐0.408) | <.001 |
| Other | 0.137 (0.129‐0.145) | <.001 | 0.168 (0.150‐0.188) | <.001 | 0.149 (0.110‐0.202) | <.001 | 0.229 (0.141‐0.369) | <.001 |
| Grade | <.001 | <.001 | <.001 | <.001 | ||||
| I | 1 | 1 | 1 | 1 | ||||
| II | 2.239 (2.030‐2.469) | <.001 | 1.868 (1.555‐2.243) | <.001 | 1.849 (1.097‐3.117) | .021 | 1.714 (0.693‐4.243) | .244 |
| III | 3.501 (3.155‐3.884) | <.001 | 2.656 (2.183‐3.232) | <001 | 4.918 (2.881‐8.397) | <.001 | 3.406 (1.039‐11.166) | .002 |
| IV | 3.949 (3.466‐4.499) | <.001 | 2.720 (2.106‐3.514) | <.001 | 5.895 (3.180‐10.931) | <.001 | 4.298 (1.691‐10.923) | .043 |
| Histological type | <.001 | .150 | <.001 | .504 | ||||
| AD | 1 | 1 | 1 | 1 | ||||
| MAD | 1.663 (1.272‐2.176) | <.001 | 1.452 (0.910‐2.316) | .117 | 1.036 (0.721‐1.488) | .848 | 1.180 (0.165‐8.451) | .869 |
| SRCC | 1.897 (1.463‐2.460) | <.001 | 1.328 (0.817‐2.160) | 252 | 4.326 (2.614‐7.158) | <.001 | 0.725 (0.087‐6.026) | .766 |
| Tumor size | <.001 | <001 | <.001 | <.001 | ||||
| <5 | 1 | 1 | 1 | 1 | ||||
| ≥5 | 1.795 (1.727‐1.866) | <.001 | 1.912 (1.770‐2.066) | <.001 | 1.864 (1.530‐2.271) | <.001 | 2.262 (1.560‐3.280) | <.001 |
| LNH | <.001 | <.001 | .012 | .431 | ||||
| <12 | 1 | 1 | 1 | 1 | ||||
| ≥12 | 0.902 (0.860‐0.946) | <.001 | 0.818 (0.749‐0.893) | <.001 | 0.754 (0.605‐0.940) | .012 | 0.831 (0.523‐1.318) | .431 |
| T stage | <.001 | <.001 | <.001 | <.001 | ||||
| T1 | 1 | 1 | 1 | 1 | ||||
| T2 | 1.637 (1.394‐1.922) | <.001 | 1.141 (0.837‐1.557) | .404 | 1.058 (0.504‐2.221) | .881 | 1.588 (0.448‐5.627) | .474 |
| T3 | 9.023 (7.946‐10.246) | <.001 | 6.181 (4.914‐7.774) | <.001 | 4.152 (2.412‐7.147) | <.001 | 4.992 (1.818‐13.702) | <.001 |
| T4 | 20.870 (18.342‐23.747) | <.001 | 15.019 (11.909‐18.942) | <.001 | 14.582 (8.475‐25.088) | <.001 | 12.225 (4.404‐33.935) | <.001 |
| N stage | <.001 | <.001 | <.001 | <.001 | ||||
| N0 | 1 | 1 | 1 | 1 | ||||
| N1 | 5.221 (4.947‐5.511) | <.001 | 4.611 (4.147‐5.127) | <.001 | 3.868 (2.894‐5.171) | <.001 | 2.761 (1.693‐4.503) | <.001 |
| N2 | 11.952 (11.326‐12.613) | <.001 | 9.130 (8.225‐10.136) | <.001 | 11.454 (8.767‐14.964) | <.001 | 7.488 (4.788‐11.713) | <.001 |
Abbreviations: HR, hazard ratio; CI, confidence interval; CEA, carcinoembryonic antigen; AD, adenocarcinoma; MAD, mucinous adenocarcinoma; SRCC, signet‐ring cell carcinoma; LNH, lymph node harvested.